SCHEMBL6028335

SCHEMBL6028335

CCc1cccc(C)c1CNc1nc(OC)cc2c1nc(C)n2C

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 10/20 0.54
CYP2C9 P11712 10/20 0.54
CYP2C19 P33261 9/20 0.54
CYP1A2 P05177 8/20 0.54
CYP2D6 P10635 5/20 0.48
RAB9A P51151 3/20 0.41
NPC1 O15118 2/20 0.41
ALDH1A1 P00352 3/20 0.36
KDM4E B2RXH2 2/20 0.36
HSD17B10 Q99714 2/20 0.36
TP53 P04637 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
GFER P55789 1/20 0.36
PIK3CD O00329 1/20 0.33
P2RX7 Q99572 1/20 0.33
MAPT P10636 1/20 0.33
EIF2AK1 Q9BQI3 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6027411 0.89 CYP3A4 (0.56) CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6
SCHEMBL6028099 0.89 CYP3A4 (0.52) CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6
SCHEMBL6027656 0.83 CYP3A4 (0.54) CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6
SCHEMBL6028379 0.83 CYP1A2 (0.51) CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6
SCHEMBL6028005 0.82 CYP3A4 (0.53) CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6
SCHEMBL6027454 0.82 CYP3A4 (0.52) CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6
SCHEMBL4908106 0.81 CYP3A4 (0.51) CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6
SCHEMBL6110394 0.81 CYP3A4 (0.51) CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6
SCHEMBL5901831 0.77 CYP3A4 (0.59) CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6
SCHEMBL5901795 0.74 CYP3A4 (0.56) CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060194782-A1 Pharmacologically active imidazo[4,5-c] pyridines ALTANA PHARMA AG (DE) 2006-08-31 US disclosed
EP-1670795-A1 PHARMACOLOGICALLY ACTIVE IMIDAZO 4,5-C PYRIDINES ALTANA Pharma AG (DE) 2006-06-21 EP disclosed
WO-2005026164-A1 PHARMACOLOGICALLY ACTIVE IMIDAZO[4,5-C]PYRIDINES ALTANA PHARMA AG (DE) 2005-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194782-A1 Pharmacologically active imidazo[4,5-c] pyridines GIPR, VIP, PGC CYP3A4 29/4885CYP2C9 578/4885CYP2C19 161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.